Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Acorda Therapeutics, Inc. (NASDAQ: ACOR).

Full DD Report for ACOR

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACOR)

Detailed Research: Economic Perspectives on First American, Greenhill & Co., Acorda Therapeutics, Deckers Outdoor, World Fuel Services, and Spirit Aerosystems - What Drives Growth in Today's Competitive Landscape
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First American Corporation (NYSE:FAF), Greenhill & Co., Inc. (NYSE:GHL...
Source: GlobeNewswire
Date: May, 15 2018 07:55
Acorda Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 03 2018 13:16
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q1 2018 Results - Earnings Call Transcript
Acorda Therapeutics, Inc. (ACOR) Q1 2018 Earnings Conference Call May 02, 2018, 08:30 AM ET Executives Felicia Vonella - Director of IR Ron Cohen - President and CEO David Lawrence - Chief, Business Operations and Principal Accounting Officer Analysts Phil Nadeau - Cowen an...
Source: SeekingAlpha
Date: May, 02 2018 13:31
Acorda Therapeutics misses by $0.33, misses on revenue
Acorda Therapeutics (NASDAQ: ACOR ): Q1 EPS of $0.14 misses by $0.33 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 02 2018 06:01
Acorda Provides Financial and Pipeline Update for First Quarter 2018
FDA accepted INBRIJA™ (levodopa inhalation powder) NDA; PDUFA date October 5, 2018 Marketing Authorization Application (MAA) for INBRIJA submitted to the European Medicines Agency (EMA) on March 26, 2018 AMPYRA ® (dalfampridine) 1Q 2018 net sales of $103 million; reite...
Source: Business Wire
Date: May, 02 2018 06:00
Notable earnings before Wednesday's open
ABC , ACOR , ADP , ALE , AME , AMRN , APTV , ARCC , ASC , AVA , BDC , BG , BPMC , CAMT , CBRE , CDW , CHK , CLH , CLX , CPLA , CRTO , CVS , DBD , DIN , DNOW , EGL , EL , ENBL , ENR , EXC , FLOW , FUN , GIB , GLDD , GNRC , GRMN , HFC , HRS , HSC , HUM ...
Source: SeekingAlpha
Date: May, 01 2018 17:30
Institutional Top Ideas Series: Scopia Capital
In the last entry of this series, we took a look at top ideas from DAFNA Capital Management (whose performance practically tripled that of the IBB during the time frame we looked at). Going forward, I hope to continue to delve into the portfolios of successful hedge funds predominantly i...
Source: SeekingAlpha
Date: April, 19 2018 12:12
Acorda to Present New Data For INBRIJA(TM) (levodopa inhalation powder) at 70th American Academy of Neurology Annual Meeting
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present new data for INBRIJA during four oral platform presentations at the upcoming American Academy of Neurology Annual Meeting in Los Angeles, taking place April 21–27, 2018. INBRIJA is an investigational inhaled levodopa treatment for ...
Source: Business Wire
Date: April, 16 2018 07:00
Acorda First Quarter Update: Webcast/Conference Call Scheduled for May 2, 2018
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its first quarter 2018 financial results on Wednesday, May 2 at 8:30 a.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647) 689-4181 (international) and ...
Source: Business Wire
Date: April, 11 2018 07:00
Acorda Files Marketing Authorization Application for INBRIJA(TM) (levodopa inhalation powder)
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA. Acorda is seeking marketing approval in the European Union for INBRIJA, an investigational inhaled levodopa treatment...
Source: Business Wire
Date: March, 26 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1724.4024.1524.6024.05348,700
2017-02-0220.9021.1021.3520.70610,873
2017-02-0120.8520.9521.2520.15532,854
2017-01-3119.4520.5020.7019.30668,386
2017-01-3020.2019.6021.0019.50483,348

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1537,82059,36663.7065Short
2018-08-1474,688117,12163.7699Short
2018-08-1345,74957,33979.7869Short
2018-08-1027,11934,99777.4895Short
2018-08-0919,04332,86757.9396Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACOR.


About Acorda Therapeutics, Inc. (NASDAQ: ACOR)

Logo for Acorda Therapeutics, Inc. (NASDAQ: ACOR)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,163,461,422 - 05/14/2018
  • Issue and Outstanding: 46,913,767 - 02/20/2018

 


Recent Filings from (NASDAQ: ACOR)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: March, 09 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018

 

 


Daily Technical Chart for (NASDAQ: ACOR)

Daily Technical Chart for (NASDAQ: ACOR)


Stay tuned for daily updates and more on (NASDAQ: ACOR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACOR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACOR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ACOR and does not buy, sell, or trade any shares of ACOR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/